Identification
- Generic Name
- Flubendazole
- DrugBank Accession Number
- DB08974
- Background
Flubendazole is an anthelmintic that is used to treat worm infection in humans. It is available OTC in Europe.
- Type
- Small Molecule
- Groups
- Experimental, Withdrawn
- Structure
Structure for Flubendazole (DB08974)
- Weight
- Average: 313.2832
Monoisotopic: 313.08626947 - Chemical Formula
- C16H12FN3O3
- Synonyms
- (5-(4-fluorobenzoyl)-1H-benzimidazole-2-yl)carbamic acid methyl ester
- Flubendazol
- Flubendazole
- Flubendazolum
- methyl 5-(p-fluorobenzoyl)-2-benzimidazolecarbamate
- External IDs
- R 17,889
- R-17,889
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Helminthic infection •••••••••••• ••••••• ••••••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareMethotrexate The excretion of Methotrexate can be decreased when combined with Flubendazole. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Flubenol / Flumoxal
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Zelcom Tablet 500 mg/1 Oral OASIS TRADING 2018-11-15 Not applicable US 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Zelcom Flubendazole (500 mg/1) Tablet Oral OASIS TRADING 2018-11-15 Not applicable US
Categories
- ATC Codes
- P02CA05 — Flubendazole
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzophenones
- Direct Parent
- Benzophenones
- Alternative Parents
- Aryl-phenylketones / Benzimidazoles / Benzoyl derivatives / Fluorobenzenes / Aryl fluorides / Imidazoles / Heteroaromatic compounds / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids and derivatives / Azacyclic compounds show 5 more
- Substituents
- Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Aryl ketone / Aryl-phenylketone / Azacycle / Azole / Benzimidazole / Benzophenone / Benzoyl show 18 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- organofluorine compound, carbamate ester, aromatic ketone, benzimidazoles (CHEBI:77095)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- R8M46911LR
- CAS number
- 31430-15-6
- InChI Key
- CPEUVMUXAHMANV-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H12FN3O3/c1-23-16(22)20-15-18-12-7-4-10(8-13(12)19-15)14(21)9-2-5-11(17)6-3-9/h2-8H,1H3,(H2,18,19,20,22)
- IUPAC Name
- methyl N-[5-(4-fluorobenzoyl)-1H-1,3-benzodiazol-2-yl]carbamate
- SMILES
- COC(=O)NC1=NC2=C(N1)C=CC(=C2)C(=O)C1=CC=C(F)C=C1
References
- Synthesis Reference
U.S. Patent 3,657,267.
- General References
- Not Available
- External Links
- KEGG Drug
- D04200
- PubChem Compound
- 35802
- PubChem Substance
- 310264937
- ChemSpider
- 32932
- 25096
- ChEBI
- 77095
- ChEMBL
- CHEMBL1454946
- ZINC
- ZINC000003830847
- Wikipedia
- Flubendazole
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suspension Oral 0.2 g Tablet Oral 500 mg Suspension Oral 2 g Tablet Oral 100 mg Tablet Oral 300 mg Suspension Oral 2000 mg Capsule, coated Oral 300 mg Tablet Oral 500 mg/1 - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) > 260 U.S. Patent 3,657,267. - Predicted Properties
Property Value Source Water Solubility 0.0288 mg/mL ALOGPS logP 2.87 ALOGPS logP 3.4 Chemaxon logS -4 ALOGPS pKa (Strongest Acidic) 9.17 Chemaxon pKa (Strongest Basic) 3.42 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 84.08 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 81.72 m3·mol-1 Chemaxon Polarizability 31.16 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 174.75896 predictedDeepCCS 1.0 (2019) [M+H]+ 177.16518 predictedDeepCCS 1.0 (2019) [M+Na]+ 184.32634 predictedDeepCCS 1.0 (2019)
Drug created at June 09, 2014 20:19 / Updated at February 21, 2021 18:52